Senolytics for Secondary Progressive MS

NCT07270120 | Not Yet Recruiting Phase 1 DMC FDA Drug

• 1 other identifier: STUDY20251750
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities. The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a MS disease-modifying therapy and have noticed their MS symptoms getting worse. People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months. These medicines work together to remove old, damaged cells that may cause inflammation and slow the repair of nerves. Participants will also be followed for one year from enrollment to monitor for treatment effects.

Conditions

Multiple Sclerosis (MS) Secondary Progressive

Keywords

senolytic; multiple sclerosis

Outcome Measures

Primary Outcomes (3)

• Participant retention rate

  Participant retention rate with D+Q therapy with no more than one missed study visit

  Baseline until 3 months

• Recruitment feasibility

  The number of subjects screened to identify eligible participants

  Baseline

• Frequency of adverse drug effects of dasatinib and quercetin

  Frequency of adverse drug effects of dasatinib and quercetin

  From baseline through study completion at 1 year

Study Arms (1)

Treatment

EXPERIMENTAL

Dasatinib and quercetin

Drug: Dasatinib and quercetin

Interventions

Dasatinib and quercetin DRUG

Participants will receive 100 mg of dasatinib and 1250 mg of quercetin orally once a day for 2 days every 2 weeks over 12 consecutive weeks

Also known as: D+Q

Treatment

Eligibility Criteria

• Age: 50 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Individuals aged 50-85 with SPMS diagnosed using the 2024 McDonald Criteria
• Not treated with a DMT for MS within the last 6 months or have used alemtuzumab, cladribine, or mitoxantrone.
• Evidence of MS progression over the past 12 months.

You may not qualify if:

• Unstable coronary artery disease (myocardial infarction within 6 months or angina)
• Hospitalization within 6 months
• Stroke or transient ischemic attack in the past 6 months
• Pulmonary arterial hypertension
• Current or chronic history of liver disease
• Alzheimer's or Parkinson's disease
• Drug or alcohol abuse in the previous 5 years
• History of coagulation disorders, central nervous system hemorrhage, or gastrointestinal hemorrhage
• History of angina or myocardial infarction, arrhythmia, or heart failure at any time
• QTc prolongation
• Anemia (Hgb\<9), thrombocytopenia (platelets\<50,000 per microliter), or neutropenia (ANC\< 1000 per microliter)
• Moderate hypokalemia (2.9 mmol/L) and moderate hypomagnesemia (0.9-1.1 mg/dL or 0.37-0.45 mmol/L)
• ALT/AST \>1.5x ULN, total bilirubin \>ULN, and alkaline phosphatase \>2x ULN
• Chronic renal disease (glomerular filtration rate \< 30 mL/min/1.73 m2)
• Alcohol intake greater than 2 drinks/day for men and greater than 1 drink/day for women

Sponsors & Collaborators

• Ohio State University: lead

Study Sites (1)

Ohio State Martha Morehouse Outpatient Care

Columbus, Ohio, 43210, United States

Location

MeSH Terms

Conditions

Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis

Interventions

Dasatinib; Quercetin

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Thiazoles; Sulfur Compounds; Organic Chemicals; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Pyrimidines; Flavonols; Flavonoids; Chromones; Benzopyrans; Pyrans; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: November 19, 2025
• First Posted: December 8, 2025
• Study Start: January 15, 2026
• Primary Completion (Estimated): January 15, 2027
• Study Completion (Estimated): January 15, 2028
• Last Updated: December 8, 2025

Record last verified: 2025-12

Locations

US (1)